MaxCyte Analyst Ratings
MaxCyte Analyst Ratings
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price MaxCyte (MXCT) is trading at is $2.61, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | 359.77% | Stephens & Co. | → $12 | Reiterates | Overweight → Overweight |
| 03/28/2023 | 359.77% | Stephens & Co. | → $12 | Reiterates | → Overweight |
| 08/15/2022 | 321.46% | BTIG | $10 → $11 | Maintains | Buy |
| 08/24/2021 | 627.97% | Stephens & Co. | → $19 | Initiates Coverage On | → Overweight |
| 08/24/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/24/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/24/2021 | 589.66% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 08/24/2021 | 742.91% | BTIG | → $22 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/05/2023 | 359.77% | 斯蒂芬斯公司 | →$12 | 重申 | 超重→超重 |
| 03/28/2023 | 359.77% | 斯蒂芬斯公司 | →$12 | 重申 | →超重 |
| 2022年08月15日 | 321.46% | BTIG | $10→$11 | 維護 | 買 |
| 2021/08/24 | 627.97% | 斯蒂芬斯公司 | →$19 | 開始承保 | →超重 |
| 2021/08/24 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 2021/08/24 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2021/08/24 | 589.66% | Stifel | →$18 | 開始承保 | →購買 |
| 2021/08/24 | 742.91% | BTIG | →$22 | 開始承保 | →購買 |
What is the target price for MaxCyte (MXCT)?
美贊臣(MaxCyte)的目標價是多少？
The latest price target for MaxCyte (NASDAQ: MXCT) was reported by Stephens & Co. on October 5, 2023. The analyst firm set a price target for $12.00 expecting MXCT to rise to within 12 months (a possible 359.77% upside). 2 analyst firms have reported ratings in the last year.
史蒂芬斯公司於2023年10月5日報道了MaxCyte(納斯達克代碼：MXCT)的最新目標價。這家分析公司將目標價定為12美元，預計MXCT將在12個月內上漲(可能上漲359.77%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for MaxCyte (MXCT)?
最新分析師對MaxCyte的評級是多少？
The latest analyst rating for MaxCyte (NASDAQ: MXCT) was provided by Stephens & Co., and MaxCyte reiterated their overweight rating.
最新分析師對MaxCyte(納斯達克代碼：MXCT)的評級由Stephens&Co.提供，MaxCyte重申其增持評級。
When is the next analyst rating going to be posted or updated for MaxCyte (MXCT)?
MaxCyte(MXCT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MaxCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MaxCyte was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與MaxCyte的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。MaxCyte的上一次評級是在2023年10月5日提交的，所以你應該預計下一次評級將在2024年10月5日左右的某個時候提供。
Is the Analyst Rating MaxCyte (MXCT) correct?
分析師評級MaxCyte(MXCT)正確嗎？
While ratings are subjective and will change, the latest MaxCyte (MXCT) rating was a reiterated with a price target of $0.00 to $12.00. The current price MaxCyte (MXCT) is trading at is $2.61, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的MaxCyte(MXCT)評級被重申，目標價在0.00美元至12.00美元之間。目前MaxCyte的交易價格為2.61美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。